PSI Advisors’s Aldeyra Therapeutics ALDX Stock Holding History

PSI Advisors’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-650	Closed	-$3.74K	–	131
2025 Q1	$3.74K	Hold	650	–	–	﹤0.01%	551
2024 Q4	$3.24K	Hold	650	–	–	﹤0.01%	675
2024 Q3	$3.5K	Hold	650	–	–	﹤0.01%	701
2024 Q2	$2.15K	Hold	650	–	–	﹤0.01%	710
2024 Q1	$2.13K	Hold	650	–	–	﹤0.01%	664
2023 Q4	$2.28K	Buy	650 +150	+30%	+$463	﹤0.01%	707
2023 Q3	$3.34K	Hold	500	–	–	﹤0.01%	639
2023 Q2	$4.2K	Hold	500	–	–	﹤0.01%	603
2023 Q1	$4.96K	Hold	500	–	–	﹤0.01%	534
2022 Q4	$3.48K	Hold	500	–	–	﹤0.01%	558
2022 Q3	$3K	Hold	500	–	–	﹤0.01%	578
2022 Q2	$2K	Hold	500	–	–	﹤0.01%	652
2022 Q1	$2K	Hold	500	–	–	﹤0.01%	610
2021 Q4	$2K	Hold	500	–	–	﹤0.01%	651
2021 Q3	$4K	Buy	+500	New	+$4.59K	﹤0.01%	591

Other funds holding ALDX

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AAP

Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PSI Advisors's ALDX Position: Q2 2025 in Review

PSI Advisors sold out of Aldeyra Therapeutics (ALDX) in Q2 2025, closing a stake of 650 shares — an estimated $3.74K sold.

PSI Advisors first reported a position in ALDX in Q3 2021 and held it in 15 quarters. The position peaked at $4.96K in Q1 2023. 121 funds tracked by Wall St. Rank hold ALDX as of Q2 2025.

PSI Advisors reported no remaining Aldeyra Therapeutics position as of Q2 2025 after selling out during the quarter.
PSI Advisors sold 650 Aldeyra Therapeutics shares in Q2 2025, an estimated $3.74K.
PSI Advisors first reported a position in Aldeyra Therapeutics in Q3 2021 and held it in 15 quarters.
PSI Advisors's Aldeyra Therapeutics position peaked at $4.96K in Q1 2023.
121 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2025.

Based on PSI Advisors's 13F filing for Q2 2025, filed 12 Aug 2025.